XXXX : a 24 year experience of a tertiary care hospital in pakistan.

@entity1 @entity3329 @entity172 @entity0 @entity2675 @entity1420 @entity5 @entity513 @entity34
BACKGROUND: @entity2675 accounts for less than 1% of all @entity5 found in @entity1 . It usually presents at a later age and stage as compared to female @entity0 . Treatment strategies are extrapolated from the management of female @entity0 . Our study here looked at 18 @entity1 diagnosed with and treated for @entity2675 at The Aga Khan University Hospital in Pakistan. We compared our findings with the existing data from Asian and Western countries. MATERIALS AND METHODS: A retrospective study was conducted looking at @entity1 with @entity2675 between January 1986 and December 2009. @entity1 and disease characteristics were analyzed and 5 year overall survival was calculated using Microsoft Excel and SPSS. RESULTS: The average age at diagnosis was 52 years (38-67 years). Twelve (66.7%) @entity1 had @entity3329 . @entity34 was the most common stage at presentation (9 @entity1 , 50%). @entity513 was seen in 16 @entity1 (88.8%). Seven lesions were positive for both @entity172 and @entity1420 receptors. Sixteen @entity1 had surgery in the form of either modified radical mastectomy or radical mastectomy. Radiation was used in 7 @entity1 in an adjuvant setting. The five year overall survival for stage I, II, III and IV disease was 100% vs 78% vs 50% vs 0%( p<0.05). Five year overall survival was 61%. None of the other prognostic factors were statistically significant. Median follow up was 15 months (3-202 months). CONCLUSIONS: @entity2675 may be on a slow rise but is still an uncommon disease. @entity5 stage and lymph node status are important prognostic markers. Public awareness and screening may help in detecting the disease at an earlier stage. Prospective trials are needed to improve the management of this disease.
